The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe

Lançon, Christophe; Toumi, Mondher; Sapin, Christophe; Hansen, Karina
January 2008
BMC Psychiatry;2008, Vol. 8, Special section p1
Academic Journal
Background: After sertindole's suspension, health authorities established a specific named-patient use (NPU) programme in order to supply sertindole to patients who did not respond to or did not tolerate alternative treatments. This programme provided the possibility of prospectively following an exhaustive cohort of patients treated with sertindole after its suspension. A survey was performed to assess sertindole's modalities of prescription, assess and document any serious adverse events (SAEs), and assess the mortality rate within the NPU cohort. Methods: The study comprised a survey of sertindole-treated patients in eleven European countries. All patients treated with sertindole within the NPU programme were eligible for the study. Results: 1,432 patients were included in the study. The reason for sertindole prescription was lack of efficacy (approximately 50%) or adverse events (approximately 20%) of other antipsychotic treatments. The mean sertindole dose was 13.4 mg daily. Lack of efficacy and adverse events were reported as reasons for sertindole discontinuation. A total of 97 SAEs were recorded, including ten fatal outcomes, which occurred during the study period or within thirty days after sertindole discontinuation. The all-cause mortality rate was 0.51 per 100 Person-Years of Exposure (95% Poisson confidence interval: 0.23-0.97). QTc prolongation was reported in 15 patients (1.05% of total patients), being a rate of 0.85 per 100 Person-Years of Exposure [95% CI: 0.48-1.41]. Conclusion: Although prescribing and supplying sertindole were subject to administrative constraints, a significant number of patients were treated with sertindole, thus supporting the need for sertindole in specific cases. Trial registration number: Not applicable.


Related Articles

  • Long-Term Outcome of Polymyositis Treated with High Single-Dose Alternate-Day Prednisolone Therapy. Uchino, Makoto; Yamashita, Satoshi; Uchino, Katsuhisa; Hara, Akio; Koide, Tatsuya; Suga, Tomohiro; Hirahara, Tomoo; Kimura, En; Yamashita, Taro; Ueda, Akihiko; Kurisaki, Ryoichi; Suzuki, Junko; Honda, Shoji; Maeda, Yasushi; Hirano, Teruyuki // European Neurology;2012, Vol. 68 Issue 2, p117 

    Background: We previously reported no difference in the efficacies of high-dose alternate-day (ADT) and daily-dose (DDT) prednisolone therapies in myositis patients, but that the incidence of side effects was lower in the former. The aim of the present study was to compare the long-term outcomes...

  • ANTIPSYCHOTICS LEAD TO WEIGHT GAIN IN PEDIATRIC PATIENTS.  // Contemporary Pediatrics;Nov2009, Vol. 26 Issue 11, p11 

    The article discusses research on the link between antipsychotics and weight gain in children. It references a study published in the October 28, 2009 issue of the "Journal of the American Medical Association." The study included 205 pediatric patients diagnosed with mood spectrum, schizophrenia...

  • Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval. Dallaire, Susie // CMAJ: Canadian Medical Association Journal;1/09/2001, Vol. 164 Issue 1, p91 

    Reports that the drugs Thioridazine (Mellaril) and mesoridazine (Serentil) may cause adverse reactions. How the drugs are used as tranquilizers or antipsychotics; Association of Mellaril and Serentil with arrhythmias and sudden death; Recommendation that the drugs be used only for schizophrenic...

  • Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;4/30/2002, Vol. 166 Issue 9, p1185 

    Reports on the health risks associated with the dibenzodiazepine antipsychotic drug clozapine (Clozaril). Association of the drug with myocarditis, cardiomyopathy and heart failure; Details of the drug; Discussion of other adverse effects, including agranulocytosis, seizures, venous...

  • A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Day, Jennifer C.; Wood, Graham; Dewey, Mike; Bentall, Richard P.; Day, J C; Wood, G; Dewey, M; Bentall, R P // British Journal of Psychiatry;May95, Vol. 166, p650 

    Background: A study was conducted to validate a comprehensive self-rating scale for measuring side-effects of neuroleptic drugs.Method: The Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS), which includes 'red herring' items, was twice administered to...

  • Opioid use − multiple concerns.  // Reactions Weekly;Mar2014, Vol. 1493 Issue 1, p4 

    The article reports on several studies regarding opioid use in the U.S. According to the results of a U.S. study, opioids should not be prescribed for adolescents with headache. Another U.S. study revealed that high-risk use of prescription opioids is associated with increased overdose...

  • Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study. Lakomy, Radek; Rogowski, Wojciech; Piko, Bela; Mihaylova, Zh; Pritzova, Eva; Kvocekova, Lucia // Cancer Management & Research;2015, Vol. 7, p311 

    Purpose: Epidermal growth factor receptor-targeted monoclonal antibodies are active as monotherapy beyond second-line treatment. Skin toxicities (STs) are common during treatment, and a positive association between ST severity and patient outcome has been reported. This study collected...

  • Impact of highly active antiretroviral therapy (HAART) on clinical outcomes of vertically HIV-1 infected children. Palladino, Claudia; Bellón, Jose María; Muñoz, Laura Díaz; Alonso, Dolores Garcia; Muñoz-Fernandez, MaÁngeles // Retrovirology;2008 Supplement 1, Vol. 5, Special section p1 

    Introduction The use of antiretroviral therapy produced a decrease in morbidity and mortality rates in human immunodeficiency virus type 1 (HIV-1)-infected children. Objectives To update a previous epidemiological survey that demonstrated the benefits of HAART on the clinical outcome of HIV-1...

  • The Problems with CATIE Phase 1: Looking Back--What the Clinician Needs to Know. Washburn Jr., Carl F. // Connecticut Medicine;Apr2008, Vol. 72 Issue 4, p223 

    The article discusses the problems with the Clinical Antipsychotic Trials of Interventional Effectiveness (CATIE) Phase 1 Trial, which was intended as a randomized and controlled clinical trial comparing the second-generation antipsychotic (SGA) agents risperidone, olanzapine, quetiapine and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics